Zimbabwe has declined a major US health deal valued at $367m (£272m) spanning five years because of Washington's request for confidential information.
The decision came to light following a government memo from December was leaked, revealing that President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government spokesperson has since clarified that the US was seeking biological samples for scientific study and commercial purposes but refused to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more negotiations to secure a deal acceptable to both sides so the nation's critical HIV treatment initiative can be sustained.
Wider Context
Zimbabwe's decision follows a comparable case in Kenya, where a court suspended a similar health funding agreement following legal challenges were raised about the security of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
According to statements, 16 African countries have so far signed these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any corresponding promise of access to any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery with no assurance that the end products would be accessible to our people if a new disease outbreak emerge."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its push of one-on-one health agreements were disrupting systems already established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This framework is designed to guarantee that when a country contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future collaboration might be structured in a manner that respects the independence and dignity of both nations."
Health Experts Response
Medical experts stated it acknowledged the official position, but suggested that negotiations should continue since a large portion of the country's HIV programmes depended on foreign aid.
"Where technical issues arise, including those involving information security or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," it said.
This impasse emphasises the continuing tensions between accepting much-needed foreign assistance and safeguarding a country's data in an ever more interconnected world.